EP1617872A4 - Procedes et compositions permettant de renforcer une reponse immune - Google Patents
Procedes et compositions permettant de renforcer une reponse immuneInfo
- Publication number
- EP1617872A4 EP1617872A4 EP04775877A EP04775877A EP1617872A4 EP 1617872 A4 EP1617872 A4 EP 1617872A4 EP 04775877 A EP04775877 A EP 04775877A EP 04775877 A EP04775877 A EP 04775877A EP 1617872 A4 EP1617872 A4 EP 1617872A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- enhancing
- compositions
- methods
- immune response
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46214003P | 2003-04-10 | 2003-04-10 | |
| US10/640,904 US7427629B2 (en) | 2002-08-15 | 2003-08-14 | Immunostimulatory compositions and methods of stimulating an immune response |
| US51525603P | 2003-10-29 | 2003-10-29 | |
| US53370303P | 2003-12-31 | 2003-12-31 | |
| US54542404P | 2004-02-18 | 2004-02-18 | |
| US54554204P | 2004-02-18 | 2004-02-18 | |
| PCT/US2004/011085 WO2005001022A2 (fr) | 2003-04-10 | 2004-04-09 | Procedes et compositions permettant de renforcer une reponse immune |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1617872A2 EP1617872A2 (fr) | 2006-01-25 |
| EP1617872A4 true EP1617872A4 (fr) | 2011-09-07 |
Family
ID=34923557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP04775877A Withdrawn EP1617872A4 (fr) | 2003-04-10 | 2004-04-09 | Procedes et compositions permettant de renforcer une reponse immune |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1617872A4 (fr) |
| JP (1) | JP2007514644A (fr) |
| AU (1) | AU2004252409A1 (fr) |
| CA (1) | CA2521662A1 (fr) |
| WO (1) | WO2005001022A2 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006007433A1 (de) * | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
| JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸 |
| WO2009030254A1 (fr) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes d'arn et de peptides cationiques pour transfection et immunostimulation |
| JP5721441B2 (ja) | 2008-01-31 | 2015-05-20 | キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ | 免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体 |
| WO2010037408A1 (fr) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition |
| PT2341933T (pt) | 2008-10-24 | 2018-02-13 | Glaxosmithkline Biologicals Sa | Derivados de imidazoquinolina lipidados |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| EP2449113B8 (fr) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation d'acides nucléiques avec des composants cationiques réticulés par des liaisons disulfure pour la transfection et l'immunostimulation |
| WO2013113326A1 (fr) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| MX2016005996A (es) * | 2013-11-05 | 2016-08-11 | 3M Innovative Properties Co | Formulaciones de inyeccion con base en aceite de ajonjoli. |
| WO2015149944A2 (fr) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Complexe cargo de support polymère à utiliser comme agent immunostimulant ou comme adjuvant |
| CA2998995A1 (fr) | 2015-09-29 | 2017-04-06 | Astrazeneca Aktiebolag | Composes conjugues de l'adenine et leur utilisation comme adjuvants de vaccins |
| HUE055079T2 (hu) | 2015-10-07 | 2021-10-28 | Sumitomo Dainippon Pharma Co Ltd | Pirimidin vegyületek |
| CR20180229A (es) | 2015-10-29 | 2018-08-24 | Novartis Ag | Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| AU2019311965B2 (en) | 2018-07-23 | 2026-02-19 | Japan Institute For Health Security | Composition containing influenza vaccine |
| EP3937984A1 (fr) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le her2 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0386757A2 (fr) * | 1989-03-09 | 1990-09-12 | The Johns Hopkins University School Of Medicine | Esters de polyphospho biodégradables |
| US5342940A (en) * | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
| WO1997013499A1 (fr) * | 1995-10-11 | 1997-04-17 | The University Of British Columbia | Formulations de liposomes a base de mitoxantrone |
| WO2000040228A2 (fr) * | 1999-01-08 | 2000-07-13 | 3M Innovative Properties Company | Formulations et procedes utilises pour le traitement des etats pathologiques des muqueuses au moyen d'un modificateur de la reponse immunitaire |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| WO2002046749A2 (fr) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Procede de criblage permettant d'identifier des composes qui induisent de maniere selective la production d'interferon alpha |
| CN1377648A (zh) * | 2002-04-23 | 2002-11-06 | 四川大学 | 皮肤局部用咪喹莫特或其衍生物脂质体及其制备方法和用途 |
| WO2004032829A2 (fr) * | 2002-08-15 | 2004-04-22 | 3M Innovative Properties Company | Compositions immunostimulantes et procedes de stimulation d'une reponse immune |
| WO2004060967A1 (fr) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Procedes de formation d'hydrogels au moyen de compositions de thiosulfonate et leurs utilisations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7998091A (en) * | 1990-05-17 | 1991-12-10 | Harbor Medical Devices, Inc. | Medical device polymer |
| US6486214B1 (en) * | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| US6518280B2 (en) * | 1998-12-11 | 2003-02-11 | 3M Innovative Properties Company | Imidazonaphthyridines |
| US6486168B1 (en) * | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
-
2004
- 2004-04-09 EP EP04775877A patent/EP1617872A4/fr not_active Withdrawn
- 2004-04-09 WO PCT/US2004/011085 patent/WO2005001022A2/fr not_active Ceased
- 2004-04-09 AU AU2004252409A patent/AU2004252409A1/en not_active Abandoned
- 2004-04-09 JP JP2006532393A patent/JP2007514644A/ja not_active Withdrawn
- 2004-04-09 CA CA002521662A patent/CA2521662A1/fr not_active Abandoned
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0386757A2 (fr) * | 1989-03-09 | 1990-09-12 | The Johns Hopkins University School Of Medicine | Esters de polyphospho biodégradables |
| US5342940A (en) * | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
| WO1997013499A1 (fr) * | 1995-10-11 | 1997-04-17 | The University Of British Columbia | Formulations de liposomes a base de mitoxantrone |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| WO2000040228A2 (fr) * | 1999-01-08 | 2000-07-13 | 3M Innovative Properties Company | Formulations et procedes utilises pour le traitement des etats pathologiques des muqueuses au moyen d'un modificateur de la reponse immunitaire |
| WO2002046749A2 (fr) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Procede de criblage permettant d'identifier des composes qui induisent de maniere selective la production d'interferon alpha |
| CN1377648A (zh) * | 2002-04-23 | 2002-11-06 | 四川大学 | 皮肤局部用咪喹莫特或其衍生物脂质体及其制备方法和用途 |
| WO2004032829A2 (fr) * | 2002-08-15 | 2004-04-22 | 3M Innovative Properties Company | Compositions immunostimulantes et procedes de stimulation d'une reponse immune |
| WO2004060967A1 (fr) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Procedes de formation d'hydrogels au moyen de compositions de thiosulfonate et leurs utilisations |
Non-Patent Citations (8)
| Title |
|---|
| "The Merck Index, An encyclopedia of chemicals, drugs, and biologicals 13th Edition", 1 January 2001, MERCK & CO., INC, XP007914381 * |
| ALEXIOU C ET AL: "LOCOREGIONAL CANCER TREATMENT WITH MAGNETIC DRUG TARGETING", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 60, no. 23, 1 December 2000 (2000-12-01), pages 6641 - 6648, XP001063184, ISSN: 0008-5472 * |
| HULAND EDITH ET AL: "In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 121, no. 5, 1995, pages 285 - 290, XP008140263, ISSN: 0171-5216 * |
| LAMBERT D M: "Rationale and applications of lipids as prodrug carriers", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 11, no. S2, 1 January 2000 (2000-01-01), pages S15 - S27, XP002245016, ISSN: 0928-0987, DOI: 10.1016/S0928-0987(00)00161-5 * |
| MUI B ET AL: "Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, WILLIAMS AND WILKINS CO, vol. 298, no. 3, 1 September 2001 (2001-09-01), pages 1185 - 1192, XP002228992, ISSN: 0022-3565 * |
| PACIOTTI G F ET AL: "Comparison of the toxicity and pharmacokinetics of neat and colloidal good bound TNF", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 40, 1 March 1999 (1999-03-01), pages 585, XP001537146, ISSN: 0197-016X * |
| WANG HUAN ET AL: "Comparison of Transdermal Diffusion in vitro of Imiquimod in Liposomes and Cream", ZHONGGUO YIYAO GONGYE ZAZHI - CHINESE JOURNAL OF PHARMACEUTICALS, SHANGHAI YIYAO GONGYE YANJIUYUAN, SHANGHAI, CN, vol. 34, no. 2, 1 February 2003 (2003-02-01), pages 73 - 75, XP008156372, ISSN: 1001-8255 * |
| WANG HUAN ET AL: "Preparation Technology of Imiquimod Chitosan Nanoparticle Optimized by Orthogonal Test", ZHONGGUO YAOSHI - CHINA PHARMACIST, YAOWU LIUXINGBINGXUE ZAZHISHE, HUBEI, CN, vol. 5, no. 7, 1 July 2002 (2002-07-01), pages 432 - 433, XP008156371, ISSN: 1008-049X * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1617872A2 (fr) | 2006-01-25 |
| WO2005001022A3 (fr) | 2005-09-15 |
| JP2007514644A (ja) | 2007-06-07 |
| AU2004252409A1 (en) | 2005-01-06 |
| WO2005001022A2 (fr) | 2005-01-06 |
| CA2521662A1 (fr) | 2005-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1729768A4 (fr) | Formulations modificatrices de reponse immunitaire et procedes correspondants | |
| EP1835915A4 (fr) | Formulations de modificateur de reaction immunitaire et procedes associes | |
| EP1812031A4 (fr) | Compositions et procedes de modification de biomolecules | |
| ATE402934T1 (de) | Malonamidderivate als gamma-secretaseinhibitoren | |
| ATE478868T1 (de) | Pyrrolodihydroisochinoline als pde10- inhibitoren | |
| ATE452891T1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| EP1686981A4 (fr) | Compositions et procedes de radiotherapie et de chimiotherapie combinatoires | |
| EP1701725A4 (fr) | Methodes et compositions | |
| IS8006A (is) | Setin pýrimidínón | |
| NO2014013I2 (no) | Linaclotide | |
| DE602004025258D1 (de) | Aminotriazol-verbindungen als proteinkinase-hemmer | |
| DE602004020318D1 (de) | Abbildungseinrichtung | |
| DE602004022101D1 (de) | solches system | |
| EP1612464A4 (fr) | Thermostat | |
| DE602004024888D1 (de) | Multipartikeln | |
| DK1687725T3 (da) | Sikkert betalingssystem | |
| EP1896050A4 (fr) | Procedes et compositions peptidiques lkktet et/ou lkktnt | |
| DE502004004657D1 (de) | Transversalflussmaschine | |
| MA28582B1 (fr) | Composes de thieno-pyridinone et procedes de traitement associes | |
| DE502004006055D1 (de) | 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren | |
| DE602004021269D1 (de) | 5-arylpyrimidine als anti-krebs-mittel | |
| ATA17862003A (de) | Belag aus belagsplatten | |
| DE602004018858D1 (de) | Emulsionszusammensetzung | |
| EP1991237A4 (fr) | Procedes et compositions chimioprotecteurs | |
| DE602004010464D1 (de) | Videoverarbeitung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20051110 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20110810 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/48 20060101ALI20110804BHEP Ipc: A61F 2/76 20060101ALI20110804BHEP Ipc: A61K 47/00 20060101ALI20110804BHEP Ipc: A61F 2/06 20060101ALI20110804BHEP Ipc: A61P 37/00 20060101ALI20110804BHEP Ipc: A61F 2/24 20060101ALI20110804BHEP Ipc: A61K 45/00 20060101AFI20110804BHEP |
|
| 17Q | First examination report despatched |
Effective date: 20121108 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20190123 |